The Event has Ended
The NHS Oncology Conference North 2023
08:00 am
29 Jun, 2023
etc venues Manchester
The NHS Oncology Conference North 2023
08:00 am
29 Jun, 2023
etc venues Manchester
The NHS Oncology Conference North 2023
The Convenzis Oncology Conference series aims to provide a secure and focused environment for NHS Oncology specialists to listen, learn and engage with peers and sector leaders from across the UK and further afield.
“I really enjoyed the conference, and the speakers were excellent. Thank you also for providing a seamless, quality conference experience as well “. University Hospitals Dorset NHS Foundation Trust
Cancer affects us all. Survival in England is at a record high and patients’ experience of treatment and care has never been higher, but we won’t stop there. We want every person with cancer to have the very best diagnosis, treatment and care. NHS England & Improvement
Around 40,000 fewer people than normal started cancer treatment in the UK last year. The UK’s NHS currently has more than 4·6 million people on waiting lists for surgery and 300 000 people have been on hold for more than 12 months—a wait time that is 100-times higher than before the pandemic.
Our upcoming conference will open the debate on how the NHS is planning to lean on new models of delivery and innovation to help manage the current treatment backlogs and improve outcomes on a national scale.
Here are a few examples of the amazing work already being done across the UK oncology sector:
Rapid Diagnostic Centres (RDCs): Rapid Diagnostic Centres (RDCs) are designed to speed up cancer diagnosis and support the NHS ambitions to achieve earlier diagnosis, with improved patient experience, for all patients with cancer symptoms or suspicious results.
The NHS Screening Programme: A £130 million national Radiotherapy Modernisation Fund has delivered the largest radiotherapy upgrade programme in 15 years. We have provided funding to replace or upgrade over 80 radiotherapy machines so that patients can have access to sustainable high-quality modern radiotherapy treatments wherever they live.
Proton Beam Therapy /(CAR-T) Therapy treatment for children: Proton beam therapy is a type of radiotherapy that uses a beam of high energy protons, which are small parts of atoms, rather than high energy x-rays (called photons) to treat specific types of cancer. CAR-T is a highly complex and innovative new treatment. CAR-T is a type of immunotherapy that involves collecting and using the patients’ own immune cells to treat their condition.
Providing personalised care and support interventions: The NHS Long Term Plan for Cancer stated that, ‘by 2021, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information and support.
Join us at the National NHS Oncology Conference as we explore these new areas of best practice, network with peers and share insights.
Research sources for Screening for a brighter future: NHS Oncology Virtual Conference: NHS England and improvement, Cancer Research UK
Convenzis events are highly regarded for their ability to drive strategic level change and transformation within the healthcare industry. Our events bring together senior healthcare leaders and decision-makers from across the NHS and wider healthcare sector, with the aim of identifying and implementing innovative approaches to address the most pressing challenges facing the industry today.
Exact Sciences UK, Ltd has had no input or influence on the agenda.
Headline Sponsor
The NHS Oncology Conference North 2023 Key Subjects
- The role of Genomics in Oncology
- Cancer standards: Models of care and measurement
- AI as a partner and tool
- Improving safety and outcomes
- Learning from patient experience
- Screening
- Early Detection
- New and Improved Cancer Targeted Therapies
Who will Attend
- Advanced Registered Practice Nurse
- Anaesthesiologists
- Case Managers
- Chief Technology Officers
- Clinical Nurse Specialists
- Directors/Heads of Oncology
- Clinical Directors/Heads/Leads
- Medical Directors/Heads
- Medical Imaging Directors/Heads/Managers
- Pain Specialists
- Palliative Care Specialists
- Pathologists
- Paediatric Oncologists
- Radiologists
- Surgical Oncologists
- Urologists
- Pharmacologists
- Histo Pathologist
Your Pass Includes....
Your Pass Includes:
- Multiple live keynote presentations
- Live examples of both NHS and Commercial best practice
- Breakfast, Lunch and Refreshments included
- Meet the supplier sessions.
- Networking opportunity
- Live Q&A sessions with all speakers on the day
- Drinks receptions (subject to event)
- CPD accreditation
- Prize draws
Speakers
Sponsors & Partners
The Agenda
08:00
Registration, Networking & Breakfast
Registration, Networking & Breakfast
09:00
Chairs Opening Address (Confirmed)
Avril Chester
Founder
Cancer Central
Chairs Opening Address
09:05
Routine implementation of electronic remote monitoring of symptoms in an oncology setting (Confirmed)
Dr James Price
Consultant Clinical Oncologist
The Christie NHS Foundation Trust
Electronic patient reported outcome measures (ePROMs) are used to remotely collect information regarding health status, psychological well-being and functioning directly from patients. Patients and clinicians have routinely reported high satisfaction and acceptability with using ePROMs in routine cancer care but to date much of their use has been limited to clinical trials and not in clinical practice.
At the Christie we developed an ePROMs platform, “MyChristie-MyHealth”, where patients can access and complete online questionnaires. The questionnaires include symptom-based questions relating to treatments and Quality of Life. At the end of the questionnaire, patients receive advice on the management of their symptoms based on their responses. The patient’s responses are automatically transferred to the electronic patient record system for review by clinicians.
This presentation will provide an overview of this programme of work including patient and clinician feedback and improved patient experience and clinical outcomes.
09:25
Accelerating progress on our Early Diagnosis Strategy (Confirmed)
David Fitzgerald
Programme Director, Policy and Strategy – NHS Cancer Programme
NHS England
The NHS has the ambition of diagnosing 75% of cancers at stage 1 and 2 by 2028. Join NHS Cancer Programme Director, David Fitzgerald, for this overview of our multi-faceted Early Diagnosis Strategy, and the role you have to play.
09:45
Harnessing AI in cancer care Panel discussion
Anita Grigoriadis
Reader in Cancer Bioinformatics
King’s College London
Dr Kieran Zucker
Clinical Lecturer in Health Data Science and Machine Learning Engineering, Honorary Clinical Oncology Specialist Registrar, Co-Chair of UK Faculty of Clinical Informatics (FCI)
University of Leeds, Leeds Teaching Hospitals, UK Faculty of Clinical Informatics
David Fitzgerald
Programme Director, Policy and Strategy – NHS Cancer Programme
NHS England
- Dr Anita Grigoriadis, Reader in the School of Cancer and Pharmaceutical Sciences at King’s College London (Confirmed)
- Dr Kieran Zucker, Clinical Lecturer in Health Data Science and Machine Learning Engineering, Honorary Clinical Oncology Specialist Registrar, Co-Chair of UK Faculty of Clinical Informatics (FCI), University of Leeds, Leeds Teaching Hospitals, UK Faculty of Clinical Informatics (Confirmed)
- David Fitzgerald, Programme Director, Policy and Strategy – NHS Cancer Programme, NHS England (Confirmed)
10:05
Optimising Genomic Testing and Targeted Therapy Pathways
Dr Emma Howard
Scientific Operational Director
NW GLH
Main Sponsor - The Merck Group
10:25
Q&A Panel
David Fitzgerald
Programme Director, Policy and Strategy – NHS Cancer Programme
NHS England
Dr James Price
Consultant Clinical Oncologist
The Christie NHS Foundation Trust
Dr Emma Howard
Scientific Operational Director
NW GLH
Q&A Panel
10:40
Morning Break, Networking & Refreshments
Morning Break, Networking & Refreshments
11:40
Chairs Morning Reflection
Avril Chester
Founder
Cancer Central
Chairs Morning Reflection
11:45
Reducing incidence and severity of Oral Mucositis with Photobiomodulation
James Carroll
CEO
THOR Photomedicine Ltd
Oral Mucositis is the most common and most significant side-effect of systemic chemotherapy and radiotherapy. The incidence is high (40-75%) and often leads to parenteral feeding and opioids, extended periods of hospitalisation, and a higher risk of systemic infection.
Photobiomodulation (PBM) is a low-intensity light therapy treatment recommended by the Multinational Association for Supportive Care in Cancer (MASCC) and by The National Institute for Health and Care Excellence (NICE) guidelines in the UK for preventing or treating oral mucositis.
Data from more than 50 randomised controlled clinical trials and our studies show that PBM can reduce the incidence of grade 3 or 4 Oral Mucositis by 75%. PBM utilises light in the red and near-infrared spectrum, which is absorbed by enzymes in mitochondria to increase cellular energy (ATP) production and simultaneously reduce oxidative stress (free radicals).
The downstream effects act on gene transcription factor NF-κβ to reduce inflammatory cytokines and increase keratinocyte proliferation and migration leading to tissue repair. Treatment can be applied extra-orally and intraorally, ideally, five times a week before each fraction or RT or each infusion of CT (Monday-Friday); treatment times can be as short as five minutes per session.
The benefits are improved quality of life and reduced total cost of care through reduced parenteral feeding, reduced use of opioids, and reduced rescheduling of cancer treatments. No adverse events have been reported, including no negative effects on survival or cancer reoccurrence.
12:05
Aspirant Cancer Career and Education Programme (ACCEND): Supporting those working with cancer (Confirmed)
June Davis
Lead Allied Health Professional and Nursing Adviser
Macmillan Cancer Support
This presentation will provide an overview of the ACCEND programme including the core capabilities in practice, education and career framework and the associated programme deliverables and focus.
12:25
Personalised treatment for advanced breast cancer
Andrew Proctor
Consultant Oncologist of Breast Cancer Services
York NHS Trust
Case Study - Novartis Group
This is a promotional meeting and sponsored by Novartis UK Ltd, not Novartis Group.
12:45
Q&A Panel
James Carroll
CEO
THOR Photomedicine Ltd
June Davis
Lead Allied Health Professional and Nursing Adviser
Macmillan Cancer Support
Avril Chester
Founder
Cancer Central
Andrew Proctor
Consultant Oncologist of Breast Cancer Services
York NHS Trust
Q&A Panel
12:55
Networking and Lunch
Networking and Lunch
13:55
Chairs Afternoon Address (Confirmed)
Avril Chester
Founder
Cancer Central
Chairs Afternoon Address
14:00
Exploring Computational Pathology and Artificial Intelligence in Oncology: From Histology to Outcome Prediction (Confirmed)
Anita Grigoriadis
Reader in Cancer Bioinformatics
King’s College London
Computational pathology refers to the application of computer-based techniques and algorithms to analyze and interpret histopathology images(CPATH). Advances in artificial intelligence (AI) have led to an explosion in innovation in CPATH enabling both the automation of routine diagnostic tasks, and the discovery of new prognostic and predictive biomarkers from tissue morphology alone. This new set of tools has the potential to facilitate the integration of personalised medicine into oncology, yet, to date, little of CPATH research has found its way into the clinic, hindered by technical, operational, ethical, and economic challenges. Here, I will share examples relevant to the pathologist, for diagnosis, molecular-genetic, tumour microenvironment. I will
address the more common challenges slowing clinical adoption and describe current approaches to drive forward this new paradigm of clinical pathology.
14:20
Screening and early intervention panel discussion
Dr Sarah Taylor
GP in Greater Manchester and GP Lead
GatewayC
Vicki Kong
Havering Clinical Lead for Population Health Management
NHS North East London
- Dr Sarah Taylor, GP in Greater Manchester and GP Lead, GatewayC (Confirmed)
- Vicky Kong, Havering Clinical Lead for Population Health Management, NHS North East London (Confirmed)
14:50
Drinks Reception, Networking and End of Day
Drinks Reception, Networking and End of Day
